Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Sandoz well positioned in a growing market; planned spin-off
on track for H2
FINANCIAL PROFILE
Q1 performance¹
Sales USD 2.4bn (+8%)
Biopharma grew 17%; Retail 6%
Strong ex-US sales growth:
■ EU: USD 1.4bn (+16%)
■ ROW: USD 0.6bn (+4%)
■ US: USD 0.4bn (-7%)
Core Oplnc (+3%)
Continuing to deliver
on biosimilar promise
Adalimumab HCF approved in
US, Europe; launch starting in H2
Denosumab filing accepted (US)
Aflibercept Ph3 readout in H2
Announced USD 400 million
investment for new biologics
plant (Slovenia)
On track for planned
Sandoz spin-off² in H2 2023
Capital Markets Day - June 8
(NYC) and June 12 (London)
Gilbert Ghostine appointed
as Sandoz Chairman-Designate
Expected tax neutral for Novartis
and majority of shareholders
HCF high concentration formulation. 1. All growth rates in constant currencies (cc).
26 Investor Relations | Q1 2023 Results
2. Transaction requires Novartis BoD and shareholder approval.
NOVARTIS | Reimagining MedicineView entire presentation